image description

News. Other News

Enable Injections Closes $30M Series A Financing Led by ORI Healthcare

Enable Injections Closes $30M Series A Financing Led by ORI Healthcare

Securus Medical Group, Inc. Announces Series C Financing and 510(k) Clearance

Securus Medical Group, Inc. Announces Series C Financing and 510(k) Clearance

genae Opens Offices in New York City

genae Opens Offices in New York City

Juventas to Launch Phase 3 Study Next Year

Juventas to Launch Phase 3 Study Next Year
cleveland.com, May 30, 2014

Clinic Focuses on Commercializing Medical Products

Clinic Focuses on Commercializing Medical Products
Plastics News, May 28, 2014

Juventas Therapeutics new therapeutic delivery approach trial initiated, featured in press

Juventas Therapeutics new therapeutic delivery approach trial initiated, featured in press
November 27, 2013

Cleveland Clinic-led group gets $10 million to become one of three NIH Centers for Accelerated Innovations

Cleveland Clinic-led group gets $10 million to become one of three NIH Centers for Accelerated Innovations
Angela Townsend, The Plain Dealer, September 26, 2013
Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial. The 90-patient, placebo-controlled, randomized double-blinded Phase II study is evaluating the safety and efficacy for JVS-100 in patients with late stage heart failure. Dr. Amit Patel, the Director of Clinical Regenerative Medicine at University of Utah Medical Center, treated the patient.

Global Cardiovascular Innovation Center